C83.12 Mantle cell lymphoma, intrathoracic lymph nodes

Name of the Condition

• Mantle cell lymphoma, intrathoracic lymph nodes
• Also known as ICD-10 code C83.12

Summary

Mantle cell lymphoma, intrathoracic lymph nodes, is a type of non-Hodgkin lymphoma characterized by the malignant proliferation of B-cells originating from the mantle zone of lymphoid follicles. It specifically involves abnormal growth of these cells in the intrathoracic lymph nodes, which include those in the chest cavity. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior.

Causes

The exact cause of mantle cell lymphoma, intrathoracic lymph nodes, remains unknown. It is thought to involve genetic mutations, such as the t(11;14)(q13;q32) translocation, which leads to overexpression of cyclin D1. Specific triggers or environmental factors are not well-defined, though research suggests potential links to immune system dysregulation.

Risk Factors

• Age: More common in older adults, typically over 60 years.
• Male gender: Slightly higher incidence in males.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes in the chest or thoracic region.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.
• Shortness of breath or chest discomfort (if lymph nodes compress nearby structures).

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans) to identify intrathoracic lymph node involvement, and tissue biopsy (e.g., excisional or core needle biopsy) to confirm the presence of malignant B-cells with characteristic genetic markers like cyclin D1 overexpression. Additional tests, such as bone marrow biopsy or flow cytometry, may be performed to assess disease extent.

Treatment Options

Treatment depends on the stage and aggressiveness of the disease and may include chemotherapy, immunotherapy (e.g., rituximab), targeted therapy (e.g., BTK inhibitors), radiation therapy (for localized disease), or stem cell transplantation in select cases. Clinical trials may be an option for eligible patients.

Prognosis and Follow-Up

Prognosis varies based on factors like age, overall health, and response to treatment. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance is typically recommended.

Complications

Potential complications include lymph node enlargement causing airway or vascular compression, infection due to immunosuppression, anemia, or transformation to a more aggressive lymphoma subtype.

Lifestyle & Prevention

No specific preventive measures are known. Maintaining a healthy lifestyle, avoiding known carcinogens (e.g., tobacco), and managing chronic infections may support overall health. Regular medical check-ups are advised for those with risk factors.

When to Seek Professional Help

Seek medical attention for persistent symptoms like unexplained weight loss, fever, night sweats, or chest discomfort, especially if lymph node swelling is present. Prompt evaluation is important for early diagnosis and management.

Tips for Medical Coders

Code C83.12 is specific to mantle cell lymphoma involving intrathoracic lymph nodes. Documentation should clearly specify the anatomical location (intrathoracic) and confirm the diagnosis of mantle cell lymphoma. Ensure alignment with clinical findings and avoid coding for unspecified sites when location is documented.